Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Oman.
Campus
  • RSV
Campus
  • RSV

SoliMix Study Results Summary

Discover clinical outcomes with iGlarLixi versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial leading to advancing therapy in sub-optimally controlled basal insulin-treated Type-2 diabetes.

Related articles
Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
  • Diabetes

Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

Read article
Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options
  • Diabetes

Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options

Read article
Treatment simplification of complex insulin regimens in T2D
  • Diabetes

Treatment simplification of complex insulin regimens in T2D

Read article
MAT-BH-2300623/v1/November2023